Phyrago is a drug owned by Handa Therapeutics Llc. It is protected by 6 US drug patents filed from 2023 to 2026 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 22, 2041. Details of Phyrago's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12465606 | Amorphous Solid Dispersions Of Dasatinib And Uses Thereof |
Jan, 2041
(14 years from now) | Active |
| US11202778 | Amorphous solid dispersions of dasatinib and uses thereof |
Jan, 2041
(14 years from now) | Active |
| US11324745 | Amorphous solid dispersions of dasatinib and uses thereof |
Jan, 2041
(14 years from now) | Active |
| US11298356 | Amorphous solid dispersions of dasatinib and uses thereof |
Jan, 2041
(14 years from now) | Active |
| US12433891 | Amorphous Solid Dispersions Of Dasatinib And Uses Thereof |
Jan, 2041
(14 years from now) | Active |
| US12544376 | Amorphous Solid Dispersions Of Dasatinib And Uses Thereof |
Jan, 2041
(14 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical
activities like
abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease
the life of a
patent hence affecting its expiry date and in turn affecting the generic launch date of that drug.
Tracking these
ongoing activities on a patent application helps to keep an eye on the latest developments in the
patent process of
the drug which can give an idea of how early a drug's generic could be available. The next section
provides a list of
recent legal activities on Phyrago's patents.
Latest Legal Activities on Phyrago's Patents
Given below is the list of recent legal activities going on the following patents of Phyrago.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Recordation of Patent Grant Mailed | 18 Nov, 2025 | US12465606 |
| Recordation of Patent eGrant | 11 Nov, 2025 | US12465606 |
| Patent Issue Date Used in PTA Calculation | 11 Nov, 2025 | US12465606 |
| Patent eGrant Notification | 11 Nov, 2025 | US12465606 |
| Mail Patent eGrant Notification | 11 Nov, 2025 | US12465606 |
| Email Notification | 11 Nov, 2025 | US12465606 |
| Email Notification | 30 Oct, 2025 | US12465606 |
| Issue Notification Mailed | 29 Oct, 2025 | US12465606 |
| Application Is Considered Ready for Issue | 17 Oct, 2025 | US12465606 |
| Dispatch to FDC | 17 Oct, 2025 | US12465606 |
FDA has granted several exclusivities to Phyrago. Till the time
these exclusivities
are active, no other company can market a generic or bioequivalent version of Phyrago, regardless of the status of it's patents. These exclusivities hence play a crucial role in
delaying the generic
launch. Given below are details of the exclusivities granted to
Phyrago.
Exclusivity Information
Phyrago holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2026. Details of Phyrago's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-307) | Dec 05, 2026 |
US patents provide insights into the exclusivity only within the United States, but
Phyrago is protected by patents in multiple countries.
Understanding
the full scope
of patent protection is crucial in strategizing market entry. By looking at the broader patent
landscape, you can
identify markets with weaker patent protection which could be ideal generic entry points. The
following section offers
details on Phyrago's family patents as well as insights into
ongoing legal events
on those patents.
Phyrago's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Phyrago:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
Generic Launch
Generic Release Date:
Phyrago's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Jan 22, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Phyrago Generic API suppliers:
Dasatinib is the generic name for the brand Phyrago. 8 different companies have already filed for the generic of Phyrago, with Alembic having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Phyrago's generic
Alternative Brands for Phyrago
Phyrago which is used for treating Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL)., has several other brand drugs using the same active ingredient (Dasatinib). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Bristol Myers Squibb |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Dasatinib, Phyrago's active ingredient. Check the complete list of approved generic manufacturers for Phyrago
About Phyrago
Phyrago is a drug owned by Handa Therapeutics Llc. It is used for treating Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL). Phyrago uses Dasatinib as an active ingredient. Phyrago was launched by Handa in 2023.
Approval Date:
Phyrago was approved by FDA for market use on 05 December, 2023.
Active Ingredient:
Phyrago uses Dasatinib as the active ingredient. Check out other Drugs and Companies using Dasatinib ingredient
Treatment:
Phyrago is used for treating Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL).
Dosage:
Phyrago is available in tablet form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 20MG | TABLET | Prescription | ORAL |
| 100MG | TABLET | Prescription | ORAL |
| 140MG | TABLET | Prescription | ORAL |
| 50MG | TABLET | Prescription | ORAL |
| 70MG | TABLET | Prescription | ORAL |
| 80MG | TABLET | Prescription | ORAL |